Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biomarker

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1775033

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1775033

Neurological Biomarkers

PUBLISHED:
PAGES: 389 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Neurological Biomarkers Market to Reach US$17.1 Billion by 2030

The global market for Neurological Biomarkers estimated at US$8.8 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 11.7% over the analysis period 2024-2030. Genomic Biomarkers, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$7.5 Billion by the end of the analysis period. Growth in the Proteomic Biomarkers segment is estimated at 14.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 15.5% CAGR

The Neurological Biomarkers market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 15.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Global Neurological Biomarkers Market - Key Trends & Drivers Summarized

Why Are Neurological Biomarkers Reshaping the Diagnosis and Treatment of Brain Disorders?

Neurological biomarkers have emerged as critical tools for diagnosing, monitoring, and treating various neurological disorders, ranging from Alzheimer’s disease and Parkinson’s disease to traumatic brain injuries and multiple sclerosis. These biomarkers, which include genetic, proteomic, metabolomic, and imaging-based indicators, provide valuable insights into the pathophysiology of brain diseases, allowing for earlier and more accurate diagnoses. Unlike traditional diagnostic approaches that often rely on subjective clinical observations, neurological biomarkers offer objective, quantifiable data that enhance precision medicine initiatives. The use of cerebrospinal fluid (CSF) and blood-based biomarkers is gaining traction, enabling non-invasive and minimally invasive diagnostic methods that improve patient compliance. Additionally, advancements in neuroimaging, such as positron emission tomography (PET) and functional MRI (fMRI), have expanded biomarker research, allowing clinicians to track disease progression in real-time. The growing integration of artificial intelligence (AI) in biomarker analysis is further revolutionizing the field, making it possible to detect subtle disease-related changes that might go unnoticed through conventional methods. As demand for early detection and personalized treatment strategies increases, the neurological biomarkers market is becoming a cornerstone of modern neurology, significantly improving patient outcomes and treatment efficacy.

What Challenges Are Hindering the Widespread Adoption of Neurological Biomarkers?

Despite their potential, neurological biomarkers face several challenges that impact their clinical adoption and widespread use. One of the major obstacles is the complexity of neurological disorders, as many conditions have overlapping symptoms and multifactorial causes, making it difficult to develop highly specific and reliable biomarkers. Additionally, the high cost and technical expertise required for biomarker validation and standardization pose significant barriers, particularly in resource-limited healthcare settings. Variability in biomarker measurements across different patient populations and laboratory settings further complicates their clinical implementation, leading to concerns about reproducibility and regulatory approval. Another challenge is the need for larger, well-controlled clinical studies to establish the predictive and diagnostic value of emerging biomarkers. The slow pace of regulatory approvals for biomarker-based diagnostic tests also delays market entry, restricting the availability of cutting-edge diagnostic tools. Furthermore, patient accessibility remains an issue, as biomarker testing is not yet widely covered by insurance providers in many countries. Addressing these challenges requires greater collaboration between researchers, regulatory bodies, and healthcare providers to develop standardized, cost-effective, and clinically validated neurological biomarker solutions.

How Are Technological Innovations Transforming Neurological Biomarker Research?

The field of neurological biomarkers is undergoing a technological revolution, with innovations in genomics, proteomics, and bioinformatics accelerating the discovery and application of novel biomarkers. One of the most promising advancements is the development of liquid biopsy techniques, which allow for the detection of neurological biomarkers in blood, saliva, or urine, providing a non-invasive alternative to traditional CSF-based testing. AI and machine learning algorithms are also playing a critical role in biomarker discovery and analysis, enabling the identification of complex biomarker patterns associated with neurodegenerative diseases. The integration of multi-omics approaches, which combine genomic, transcriptomic, proteomic, and metabolomic data, is further enhancing biomarker research, providing a more comprehensive understanding of disease mechanisms. Additionally, wearable neurotechnology and digital biomarkers are gaining momentum, allowing continuous monitoring of neurological function in real-world settings. These advancements are not only improving early detection and disease monitoring but also paving the way for precision medicine approaches that tailor treatments based on an individual’s unique biomarker profile. As the industry continues to embrace cutting-edge technologies, the role of neurological biomarkers in shaping the future of neurology is becoming increasingly significant.

What Is Driving the Growth of the Neurological Biomarkers Market?

The growth in the neurological biomarkers market is driven by several factors, including the rising prevalence of neurodegenerative diseases, increasing demand for personalized medicine, and advancements in biomarker detection technologies. The global surge in Alzheimer’s disease, Parkinson’s disease, and other age-related neurological disorders is fueling the need for early diagnostic tools, accelerating biomarker research and development. The expansion of clinical trials focused on neurological diseases is also contributing to market growth, as pharmaceutical companies invest in biomarker-based drug development strategies to improve therapeutic outcomes. Additionally, regulatory support for biomarker-driven diagnostics is increasing, with agencies such as the FDA and EMA encouraging the integration of biomarkers into clinical trials and precision medicine programs. The growing adoption of digital biomarkers and remote monitoring solutions is further expanding market opportunities, enabling real-time tracking of cognitive and motor functions. Increased funding from government and private organizations is also supporting biomarker discovery efforts, fostering collaborations between academia, biotech firms, and healthcare providers. As technological innovations continue to enhance the accuracy, accessibility, and clinical utility of neurological biomarkers, the market is poised for significant expansion, driving the next wave of advancements in neurology and precision diagnostics.

SCOPE OF STUDY:

The report analyzes the Neurological Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biomarkers Type (Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers, Other Biomarkers); Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Other Applications); End-Use (Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Abcam plc
  • Agilent Technologies, Inc.
  • Beckman Coulter Diagnostics
  • BioNTech SE
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fujirebio
  • GE Healthcare
  • Illumina, Inc.
  • IXICO plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Pacific Biomarkers
  • PerkinElmer, Inc.
  • Proteome Sciences plc
  • Qiagen N.V.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP32324

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Neurological Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neurodegenerative Diseases Propels Demand for Advanced Biomarker-Based Diagnostics
    • Increasing Global Burden of Alzheimer's and Parkinson's Disease Expands Addressable Market Opportunity
    • Growing Preference for Personalized Medicine Strengthens Business Case for Neurological Biomarkers
    • Surging R&D Investments in CNS Disorders Drives Innovation and Biomarker Discovery
    • Advances in Liquid Biopsy Technologies Accelerate Demand for Non-Invasive Neurological Biomarkers
    • Increased Adoption of Digital Biomarkers and AI-Enabled Diagnostics Drives Market Expansion
    • Integration of Multi-Omics Platforms Spurs Development of High-Specificity Biomarker Panels
    • Growing Regulatory Focus on Early Disease Detection Throws the Spotlight on Biomarker Validation
    • Emergence of Point-of-Care Neurological Tests Drives Accessibility and Market Penetration
    • Rising Clinical Trials for CNS Therapies Generate Demand for Companion Diagnostic Biomarkers
    • Expansion of Neurology-Focused Biobanks Strengthens Research Infrastructure and Commercialization Potential
    • Collaborations Between Pharma and Diagnostic Companies Drive Co-Development of Biomarker Solutions
    • Favorable Reimbursement Policies in Developed Markets Sustain Growth in Clinical Adoption
    • Rising Health Awareness and Early Screening Initiatives Accelerate Demand in Emerging Markets
    • Shift Toward Preventive Healthcare Models Expands Market for Predictive Neurological Biomarkers
    • Growing Use of Biomarkers in Drug Development Pipelines Drives Pharmaceutical Adoption
    • FDA and EMA Fast-Tracking Biomarker Qualification Processes Spurs Industry Confidence and Investment
    • Advances in Neuroimaging Integration with Biomarker Data Drive Adoption of Hybrid Diagnostic Platforms
    • Increasing Utilization of Wearable Devices Throws the Spotlight on Real-Time Digital Biomarkers
    • Challenges in Standardization and Validation Pose Barriers to Widespread Clinical Adoption
    • Growing Geriatric Population Globally Drives Long-Term Demand for Neurological Diagnostics
    • Rising Incidence of Traumatic Brain Injuries and Stroke Fuels Demand for Rapid Biomarker Tests
    • Expansion of Telehealth and Remote Monitoring Platforms Drives Need for Scalable Biomarker Solutions
    • Growing Academic-Industry Collaborations Propel Translational Research and Commercial Viability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurological Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurological Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neurological Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Neurological Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Genomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Genomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Genomic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Proteomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Proteomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Proteomic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Metabolomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Metabolomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Metabolomic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Imaging Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Imaging Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Imaging Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Parkinson's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Autism Spectrum Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Autism Spectrum Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Autism Spectrum Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospital & Hospital Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospital & Hospital Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Hospital & Hospital Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Independent Clinical Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Independent Clinical Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Independent Clinical Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Neurological Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Neurological Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Neurological Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Spain 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Russia 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Neurological Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Neurological Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Australia 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: India 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: South Korea 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Neurological Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Neurological Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Neurological Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Argentina 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Brazil 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Mexico 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Neurological Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Neurological Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Neurological Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Iran 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Israel 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: UAE 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Neurological Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Neurological Biomarkers by Biomarkers Type - Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Neurological Biomarkers by Biomarkers Type - Percentage Breakdown of Value Sales for Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Neurological Biomarkers by Application - Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Neurological Biomarkers by Application - Percentage Breakdown of Value Sales for Other Applications, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis and Autism Spectrum Disorder for the Years 2015, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Neurological Biomarkers by End-Use - Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Africa 15-Year Perspective for Neurological Biomarkers by End-Use - Percentage Breakdown of Value Sales for Hospital & Hospital Laboratories End-Use, Independent Clinical Diagnostic Centers End-Use, Research Organizations End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!